4. Disclaimer Notice: The information contained in this e-mail message and its attachments is intended solely for the use of the individual(s) to whom it is addressed and may contain information that is the con fidential information of Acorn Management Partners L.L.C. ("AMP") and its subsidiaries. The Information may be about companies in which A.M.P has or may receive compensation in the future. Any material in this message should be considered as ADVERTIS E MENT ONLY. Please consult with a certified financial advisor before making any investment decisions. All information on this report should be confirmed b efore making an investment decision. Acorn Management Partners L.L.C. ("AMP") and its subsidiaries, and an y affiliates and information providers make no implied or express warranties on the information provid ed. This is not to be construed as a solicitation to buy or sell securities. As with any stock, the featured companies involve a high degree of risk and volatility, and all investors/advisors should know that they may l ose a portion or all of their investment if they decide to purchase any stock. Acorn Management Partners L .L.C. ("AMP"), its affiliates, associates, relatives and anyone associated with in any manner reserves the right to either buy or sell shares in the profiled company's stock. The Securities and Exchange Commission has compiled an extensive amount of information concerning investing, including the inherent risks involved. We encourage our readers to visit the SEC's websit e to acquire this important information. Safe Harbor Dis- closure: Acorn Management Partners L.L.C. ("AMP ") website publications may contain or incorporate by reference "forward- looking statements, including certain information with respect to plans and strategies of the featured company. As such, any statements co ntained herein or incorporated herein by reference that are not statements of historical fact may be deemed to be forward- looking statements. Without limiting the forgoing, the words "believe(s)," "anticipate(s)," "plan(s)," "expect(s)," "project(s)" and similar expressions are intended to identify forward-looking statement s. There are a number of important factors that could cause actual events or actual results of the Companies profiled herein to differ materially from these indicated by such forward-looking statements. Certain stateme nts contained herein constitute forward-looking statements within the meaning of Section 27A of the Secu rities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statem ents regarding bussiness and financing, business trends, future operating revenues and expenses. Although the Company believes that the statements are reasonable, it can give no assurances that such expectation s will prove to be correct. Investors are cautioned that any forward-looking statements made by the Comp any or contained in any and/or all profile/research reports, contain no guarantee of future performance, an d that the actual result may differ materially from those set forth in the forward-looking statements. Differen ce in results can be caused by various factors including, but not limited to, the Company's ability to be able to successfully complete planned funding agreements, to successfully market its products in competitive industries o r to effectively implement its business plan or strategies. Any statements that express or involve discus sions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, o r future events or performance are not statements of historical fact and may be "forward looking statements." Forwar d looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to diffe r materially from those presently anticipated. Forward looking statements in this action may be identified throug h the use of words such as "expects," "will," "anticipates," "estimates," "believes," "may," or by statements indicating certain actions "may," "could," or "might" occur. We encourage our readers to invest carefully and review all forms of investments and read the investor information. More information please visit http:// www.se c.gov and/or (FINRA) at: http://www.FINRA.com. Readers can review all public filings by companies at the S EC's EDGAR page. The FINRA has published information on how to invest carefully at its web site. "Full Market Awareness" A professional relations company and consulting firm" Contact: Sean McDonald smcdonald@acornmanagementpartners.com 941,208.3919 Atlanta, Georgia & Sarasota, Florida

3. Please Read our Disclaimer Notice Below: Management Dietrich A. Stephan, Ph.D.—Chairman &Chief Executive Officer, Founder Dr. Stephan is an industry veteran who is considered one of the fathers of the field of precision me dicine, having trained with the leadership of the Human Genome Project at the NIH and then going on to lead discovery research a t the Translational Genomics Research Institute and serve as professor and chairman of the Department of Human Genetics at the University of Pittsburgh. Stephan has identified the molecular basis of dozens of genetic diseases and published extensively i n journals such as Science, the New England Journal of Medicine, Nature Genetics, PNAS, and Cell. In parallel, Dr. S tephan has founded or co-founded 14 biotechnology companies and has advised an additional 12 companies. These companies ar e backed by top-tier investors such as Sequoia Capital, KPCB, Thiel Capital, and Khosla Ventures as well as corporate par tners such as Life Technologies, Pfizer, and Mayo Clinic. Sandra Rojas-Caro, M.D.---Chief Medical Officer Dr. Rojas-Caro has broad R&D leadership, executive management and team-building experience in privat e and public biotech companies and large pharma. She has been directly involved in successful global regulatory submissio ns, including an FDA and EMA approval and more than 10 investigational new drug (IND) applications. Most recently, she wa s Chief Medical Officer for Gemini Therapeutics, a company focused on redefining age-related macular degeneration (A MD) and linked disorders with precision medicine. At Gemini, she led development through several milestones, includ ing the company’s first IND and the first cohorts of genetically selected patients dosed with the company’s leading biologic therapeutic. William Mann, Ph.D., Ph.D. ---Chief Operating Officer Dr. Mann has more than 25 years of experience in the biopharma industry. Most recently, he served as the president, chief executive officer and board member of Helsinn Therapeutics U.S. In this position, he led the compan y’s transformation from a research and development-focused organization into a fully integrated and profitable commercial en tity with a portfolio that included Aloxi®, Zykadia® and Halaven®. Bill also leveraged the company’s capabilities to attract n ew partners, including Novartis for the co-promotion of Zykadia®, the first agreement of this type for Novartis Oncology U. S. Prior to Helsinn, Bill was vice president of corporate development at Sapphire Therapeutics, Inc., where he led several tra nsactions, including the licensing of anamorelin to Ono Pharmaceutical Co., and was instrumental in the sale of the company t o Helsinn Healthcare SA. Concurrently, Bill also managed Sapphire’s international Phase 2B study of anamorelin, which ha s since been approved in Japan for the treatment of cancer cachexia under the brand name, Adlumiz®. Bill began his profes sional career at Novartis, where he led a multidisciplinary drug discovery program and later served as director of business dev elopment. He received both a bachelor's degree and a doctorate in biochemistry from the University of Aberdeen, Scotland, pursued postdoctoral studies at the Rockefeller University, and went on to obtain an MBA from Rutgers University. He curr ently serves on the board of the oncology start-up, Ardan Pharma. Tony Rossomando, Ph.D . Dr. Rossomando has more than 25 years of experience as a biopharmaceutical drug developer who has su ccessfully led teams from start-up to global biotechnology companies that have established the upstream and downstream pr ocess development of biologics and peptide molecules, including RNAi/siRNA, to advance multiple programs into clinical tr ials and commercialization in several therapeutic areas of neuroscience, rare diseases, and oncology. At NeuB ase, Dr. Rossomando will be responsible for manufacturing and process development, analytical development, and biophysic al characterization in support of FDA regulatory submissions. Prior to joining NeuBase, Dr. Rossomando was Chief Process De velopment Officer at Pinetree Therapeutics, where he oversaw early-stage upstream and downstream process development for bi-specific antibodies for oncology. Previous to that, he held the following positions: Vice President of Technology Operat ions at Anokion; Senior Director of Analytical Development at Alexion Pharmaceuticals; Vice President, Early-Stage Developme nt at Synageva BioPharma (acquired by Alexion), Senior Director siRNA Bioprocessing at Alnylam Pharmaceuticals; Pri ncipal Scientist and Director, Protein Sciences at Biogen; and Staff Scientist at Bayer Corporation. Dr. Rossomando earne d a Ph.D. in microbiology at the University of Virginia, where he researched MAP kinase and MEK1 cell signaling w ith Drs. Michael Weber and Thomas Sturgill, and completed his postdoctoral training at Cold Spring Harbor Labs, where he studied the CDC2 kinase and MEK1 signaling pathways with Dr. Daniel Marshak. Robert Friedlander, M.D., M.A.---Chair, Scientific Advisory Board Dr. Friedlander is a renowned neurologist. Prior to NeuBase, he became the fourth Chairman of the De partment of Neurological Surgeons at the University of Pittsburgh School of Medicine and the University of Pitts burgh Medical Center. Prior to joining the department, Dr. Friedlander was professor of neurosurgery at Harvard Medical Sc hool and vice-chairman of neurosurgery and associate director of cerebrovascular surgery at Brigham and Women’s Hospital in Boston. Presently, Dr. Friedlander is the Walter E. Dandy Professor of Neurosurgery, Neurology and Neurobiology, and Co-Dir ector of the UPMC Neurological Institute. His work has been published in many top tier journals including Nature, Scie nce, Nature Medicine, Nature Neuroscience and PNAS, and he has been recognized through many academic awards. In 2006, he w as elected as a member of the prestigious American Society for Clinical Investigation. Dr. Friedlander is one of onl y three neurosurgeons elected as a member of the American Association of Physicians, and in 2018, he was elected to the Na tional Academy of Medicine

2. Continue Reading for Management Background... Companies Forward Progress: Clinical Development Pipeline: "Drugging the genome to increase, decrease, or edit protein function to address base causality in disease " Recent News: • NBSE Appoints Anthony Rossomando PhD as Chief Technology Office r • Demonstrates functional rescue in Myotonic Dystrophy type 1 model and allele – selective inhibition of KRAS mutations to inhibit Tumor growth • Reports financial results for second quarter of fiscal year 2021 • Gerald J. McDougall appointed to Board of Directors • NBSE appoints Dr. Sandra Rojas-Caro as CMO Addressable Markets:

1. AMP Quic k Facts NeuBase Therapeutics (NASDAQ: NBSE) Genetic Medicines NeuBase Therapeutics, Inc. (NCM: NBSE) is a biopharma company that has developed a platform technology to uniquely Drug the Genome™. NeuBase is the only company that can temporarily drug genes in the 6 billion letter human genome that, when malfunctioning, cause disease. The world- renowned Cambridge MA and Pittsburgh PA based teams are uniquely able address diseases at their root cause, not downstream where current pharmaceutical and biotechnology companies. There exist no other technologies that can address all causal mechanisms of human disease with a single precise and well tolerated approach, promising an opportunity to disrupt current approaches and become a dominant genetic medicines company in the future. The global addressable market size for the disease s that are druggable by NBSE exceeds $1 trillion USD per year. Institutional backers include Greenligh t Capital, Point72, Sio Capital and others. A CORN M ANAGEMENT P ARTNERS , LLC November 2021 NASDAQ: NBSE Price: $3.88 Date: 10/26/21 Fiscal Year: 9/30 MKT Cap : ~ $128.8 M C .O.H * : $58.84 M Institutional Ownership: ~ 32.9 % Inside Ownership : ~ 12.91 % S /O * : ~32.72 M Float : 26.61 M AVG Vol. : ~128,000 For More Information Please Call Robert Wheeler 941.217.8310 Company Overvie w Platform: • The proprietary platform technology, protected by 22 patents and applications, enables rapid and scalable drug development. • The platform is uniquely able to Drug the Genome™ to increase, decrease or edit gene function resolving all causal mechanisms of rare and common disease • The Company has shown that it can reliably generate drugs that resolve the causal genetic defect in several “undruggable” neurological, neuromuscular and oncology indications, promising enormous scalability. • The advantages of the platform enable the company to cohesively develop therapies for a wide range of rare and common diseases. Pipeline: • Every human disease is genetic whether it be rare, common, cancer or infectious disease. NeuBase has a unique platform that can address any genetic target in the genome with industry- leading precision of target engagement and tolerability. • The team is made up of seasoned drug developers drawn on from the leading pharmaceutical and biotechnology companies in the world. • A flow of data over the next months prior to filing the first investigational new drug application (IND) with FDA in 4Q2022 provides visibility into progress and de-risking events. • The second IND will be filing in 2023. Each of the first two indications (DM1 and HD) are projected to be more than $6b revenue opportunities per year. Scaling into oncology targeting the largest “undruggable” cancer-causing gene is ongoing. Market Opportunity • The global addressable market for NBSE is more than $1 trillion per year. • Short term comparable companies include Alnylam (NASDAQ: ALNY) with a market cap of $23.49b and Moderna (NASDAQ: MRNA) with a market cap of $138.91b. • The opportunity space for NBSE is larger than for the two comparable companies in the >10- year time frame given the opportunity space is larger. IP Portfolio • NeuBase holds 22 patents and applications, both in-licensed and owned that protect the platform and products • Earliest patents have 2037 expiration, not including “Hatch Waxman” extensions • Technology originally developed at Carnegie Mellon University in collaboration with Yale University Continue Reading for More Information, Recent News and Management Background...